<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01918683</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 16213</org_study_id>
    <nct_id>NCT01918683</nct_id>
  </id_info>
  <brief_title>TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients</brief_title>
  <official_title>A Pilot Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients Awaiting Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to be the initial prospective pilot investigation of the effectiveness&#xD;
      of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation.&#xD;
      No prospective clinical trials regarding the combination of TACE and SBRT in pre-transplant&#xD;
      population have been performed. We propose the trial be conducted as a pilot clinical trial&#xD;
      with the goal of enrolling 40 patients into each arm&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether the combination of stereotatic body&#xD;
      radiotherapy (SBRT) tand transarterial chemoembolization (TACE) is an effective &quot;bridging&#xD;
      therapy&quot; for patients hepatocellular carcinoma (HCC) of the liver awaiting transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>two arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>10 days</time_frame>
    <description>endpoint is OLT</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>A -Tace alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A - TACE alone (control group, current practice and treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Tace combined with SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B- TACE combined with SBRT (experimental group).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TACE transarterial chemoembolization</intervention_name>
    <arm_group_label>A -Tace alone</arm_group_label>
    <arm_group_label>B - Tace combined with SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotatic body radiotherapy (SBRT)</intervention_name>
    <arm_group_label>B - Tace combined with SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient capable of giving informed consent&#xD;
&#xD;
          -  Patient diagnosed with hepatocellular carcinoma and listed or recommended to be listed&#xD;
             for orthotopic liver transplantation at the participating institution&#xD;
&#xD;
          -  Age &gt; 18 years old&#xD;
&#xD;
          -  Meets clinical criteria for eligibility for TACE to the target lesion per&#xD;
             Interventional Radiology&#xD;
&#xD;
          -  Childs' Class A or B7&#xD;
&#xD;
          -  Eastern Clinical Oncology Group performance status 0 or 1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior radiotherapy to the upper abdomen or radioembolization of the liver&#xD;
&#xD;
          -  Prior TACE to the target lesion, RFA, or liver transplant&#xD;
&#xD;
          -  Active GI bleed within 2 weeks of study enrollment&#xD;
&#xD;
          -  Active GI ulcer disease within 4 weeks of study enrollment&#xD;
&#xD;
          -  Ascites refractory to medical therapy&#xD;
&#xD;
          -  Contraindication to receiving radiotherapy or TACE&#xD;
&#xD;
          -  Complete obstruction of portal venous flow to the segment of liver that includes the&#xD;
             target lesion&#xD;
&#xD;
          -  Contraindication to both contrast enhanced MRI and contrast enhanced CT (i.e. unable&#xD;
             to undergo follow-up imaging or SBRT treatment planning)&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Participation in another concurrent treatment protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edgar Ben-Josef, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tarita Thomas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2013</study_first_posted>
  <last_update_submitted>December 8, 2020</last_update_submitted>
  <last_update_submitted_qc>December 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

